DK3270965T3 - Cd48-antistoffer og konjugater deraf - Google Patents

Cd48-antistoffer og konjugater deraf Download PDF

Info

Publication number
DK3270965T3
DK3270965T3 DK16765773.3T DK16765773T DK3270965T3 DK 3270965 T3 DK3270965 T3 DK 3270965T3 DK 16765773 T DK16765773 T DK 16765773T DK 3270965 T3 DK3270965 T3 DK 3270965T3
Authority
DK
Denmark
Prior art keywords
conjugates
antibodies
Prior art date
Application number
DK16765773.3T
Other languages
English (en)
Inventor
Timothy Lewis
Kristine Gordon
Lori Westendorf
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of DK3270965T3 publication Critical patent/DK3270965T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK16765773.3T 2015-03-18 2016-03-17 Cd48-antistoffer og konjugater deraf DK3270965T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134981P 2015-03-18 2015-03-18
PCT/US2016/022943 WO2016149535A1 (en) 2015-03-18 2016-03-17 Cd48 antibodies and conjugates thereof

Publications (1)

Publication Number Publication Date
DK3270965T3 true DK3270965T3 (da) 2020-06-08

Family

ID=56919489

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16765773.3T DK3270965T3 (da) 2015-03-18 2016-03-17 Cd48-antistoffer og konjugater deraf

Country Status (17)

Country Link
US (2) US10722592B2 (da)
EP (2) EP3270965B1 (da)
JP (2) JP6892826B2 (da)
KR (1) KR20170128256A (da)
CN (1) CN107530422B (da)
AU (1) AU2016232839B2 (da)
BR (1) BR112017019617A2 (da)
CA (1) CA2976740A1 (da)
DK (1) DK3270965T3 (da)
EA (2) EA201992756A3 (da)
ES (1) ES2795818T3 (da)
HK (1) HK1248538A1 (da)
IL (1) IL254027B (da)
MX (1) MX2017011432A (da)
SG (1) SG11201706786UA (da)
WO (1) WO2016149535A1 (da)
ZA (1) ZA201705935B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス, インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
BR112020023623A2 (pt) 2018-05-29 2021-02-17 Intocell, Inc. derivados de benzodiazepina e seus usos
SG11202107551WA (en) * 2019-02-05 2021-08-30 Seagen Inc Anti-cd228 antibodies and antibody-drug conjugates
CA3155634A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
CA3176248A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
US20240042051A1 (en) * 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CR20230283A (es) * 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
CN117580593A (zh) 2021-05-28 2024-02-20 思进公司 蒽环霉素抗体结合物
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1997035614A1 (en) * 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
WO2005094886A1 (ja) * 2004-03-31 2005-10-13 Kirin Beer Kabushiki Kaisha Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物
KR20070038453A (ko) * 2004-04-16 2007-04-10 마크로제닉스, 인크. FcγRIIB-특이적 항체 및 그의 사용 방법
EP2722051B1 (en) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP4026840A1 (en) 2005-07-18 2022-07-13 Seagen Inc. Beta-glucuronide-linker drug conjugates
EP1964852B1 (en) * 2005-12-20 2013-04-17 SBI Biotech Co., Ltd. Anti-ilt7 antibody
EP2211904B1 (en) 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP5745854B2 (ja) * 2007-11-13 2015-07-08 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Tl1aに対するヒト化抗体
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
EP2418222B1 (en) 2009-04-10 2016-11-02 Osaka University Therapeutic agent for treating diseases in which neoplastic proliferation of plasma cells occurs
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EA201400993A1 (ru) * 2012-03-08 2015-05-29 Галозим, Инк. Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
BR112014028222A2 (pt) * 2012-05-15 2017-06-27 Seattle Genetics Inc conjugados vinculadores auto-estabilizantes.
HUE051389T2 (hu) * 2013-10-15 2021-03-01 Seagen Inc Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához

Also Published As

Publication number Publication date
EA201792055A1 (ru) 2018-01-31
CN107530422A (zh) 2018-01-02
JP2018509908A (ja) 2018-04-12
WO2016149535A1 (en) 2016-09-22
JP6892826B2 (ja) 2021-06-23
IL254027A0 (en) 2017-10-31
EP3270965A4 (en) 2018-09-05
ZA201705935B (en) 2021-01-27
EA201992756A3 (ru) 2020-06-30
US20200289661A1 (en) 2020-09-17
US20180092984A1 (en) 2018-04-05
IL254027B (en) 2021-05-31
EA035374B1 (ru) 2020-06-03
AU2016232839A1 (en) 2017-08-31
ES2795818T3 (es) 2020-11-24
US10722592B2 (en) 2020-07-28
KR20170128256A (ko) 2017-11-22
EA201992756A2 (ru) 2020-03-31
EP3270965A1 (en) 2018-01-24
MX2017011432A (es) 2017-11-10
HK1248538A1 (zh) 2018-10-19
AU2016232839B2 (en) 2021-02-25
SG11201706786UA (en) 2017-09-28
JP2020141700A (ja) 2020-09-10
EP3270965B1 (en) 2020-05-06
CN107530422B (zh) 2021-09-21
CA2976740A1 (en) 2016-09-22
BR112017019617A2 (pt) 2018-05-22
EP3662933A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
IL288391A (en) Anti-cd123 antibodies and conjugates and their history
IL290457A (en) Antibodies and their conjugates
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3515487T3 (da) Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
DK3592393T3 (da) Frigørbare konjugater
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
BR112016021717A2 (pt) anticorpos anti-egfr e conjugados anticorpo-fármaco
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3270965T3 (da) Cd48-antistoffer og konjugater deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3102244T3 (da) Antistoflægemiddelkonjugater og immuntoksiner
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3334500T3 (da) Multiligand-lægemiddelskonjugater og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf